Loading event content

Page 1

Integra LifeSciencesJ.P. Morgan Healthcare ConferenceJanuary 2026

Page 2

Slide 2 Forward-looking statements

Page 3

A global medtech leader dedicated to restoring livesDemonstrated leadershipin $9B global marketExtensive portfolio of best-in-classproductsExecuting strategictransformation Strengthening operational foundationEnabling growth and innovationSlide 3 19%LTM adjustedEBTIDA margin62.8%LTM adjustedgross margin$1.6BLTM reportedrevenue$89MLTM operating cash flow Financial metrics shown for the trailing 12-months ended Sept. 30, 2025Both adj. gross margin and adj. EBITDA margin are non-GAAP financial measures

Page 4

Neurosurgery & ENT$3.4BMid-single-digit growthTAM$9.1BMid-single-digit growth Complex Wound ReconstructionSurgical Reconstruction Private Label Global OpportunityCodman Specialty Surgical (CSS) $1.1B1 Tissue Technologies (TT)$0.5B1Instruments$2.1BLow-single-digit growthWound & Surgical Recon$3.6BMid-to-high-single-digit growthENTInstruments Neurosurgery Slide 4 Leadership in large global marketsHighly differentiated products trusted by healthcare professionals and systems 1Trailing 12-months ended Sept. 30, 2025

Page 5

Our right to win in attractive core marketsAddressing key market trends with differentiated capabilities Slide 5 Healthcare market trendsIntegra’s right to winDisease states driven by demographicsShifting point-of-care to alternate care settingsGrowing adoption of new technologiesChanging reimbursement landscapeGeopolitical driversOpportunities in international marketsCommercial excellenceNeurosurgery leadershipStrong brand equityDeep scientific expertise in tissue reconstructionClinically differentiated products

Page 6

Sign in to continue

Your watchlist and earnings event details are available after you sign in.

Advancing transformational care, delivering impactful innovation, and enriching life moments.Slide 6 Our vision

Page 7

Delivering our visionDeliver best-in-class qualityIgniteinnovationIntegra’s strategic imperativesTransform to excel and consistently deliver our financial commitmentsHorizon 2Delivering accelerated growthHorizon 1Building a sustainable foundation Drive supply chain reliability AccelerategrowthSlide 7 Solidify market leadership, build a culture of quality and execution excellence, drive company performance

Page 8

Horizon 1: Building a sustainable foundationA systemic, foundational transformation to drive consistent and reliable performanceFocus area Improved outcomes•On-time, in-full order fulfillment•Inventory management•Cash flow •End-to-end order cycle times•Productivity•Gross margin•Production yields•Product quality•Performance predictability•Disciplined portfolio & program prioritization•Operating model efficiency & change management•Execution consistency•Delivery on warning letter actions•Favorable regulatory audit outcomes•Product quality consistencyQualitySupply chainExecutionSlide 8 Manufacturing excellenceProcess capabilityTransformation and program managementQuality management systemSupply chain planning

Page 9

•Advance skin substitutes and implant-based breast reconstruction•Capitalize on reimbursement changes•PriMatrix®, SurgiMend®, Durepair®•Consistent product delivery•Expanding Neurosurgery and ENT category leadership•New technologies and market segmentsHorizon 2: Delivering accelerated growthInvesting to enable innovation and drivers of growth Slide 9 Organic and inorganic innovationSupply chain resiliency tomeet global demandReturn of Braintree product portfolioPositive shifts in skin substitutes marketClinical evidence generation New product introductions

Page 10

Integra's position aligned with potential Medicare changes under considerationReimbursement rate changes are foundational in leveling access across sites of care Slide 10 Uniquely positioned to capture opportunities from outpatient skin substitute reimbursement •Allows volume capture shifting away from physician's office•Integra portfolio priced underthe new reimbursement rate•Long-term revenue upside with no price downside•Broad portfolio capable of meeting differentiated payment rates by regulatory path, still under considerationBroad, clinically differentiated, economically-viable skin substitute portfolio across all sites of care~$1,3001$127 2ASP / cm2for Skin Substitutes2025 and prior20261 Sources: Surgical Suite IQVIA, PO, VA/DOD SmartTrak and estimates based on Medicare claims data2Provider may only bill for the units that are administered, discarded amounts are not payable by Medicare. •Under LCD coverage changes for DFUs and VLUs, Integra would have 2 of the proposed 20 products>250~20

Page 11

Integra:Restoring livesAdvancing transformational care, delivering impactful innovation, and enriching life momentsFavorable sector dynamics•Aging population•Increase in procedural volumes•Adoption of new technologies•Opportunities in international marketsFixing the foundation•Strengthening quality management system and culture •Driving execution discipline•Optimizing supply chain•Investing in capacity expansion and process capabilityHigh value, high demand portfolio•Strong brand equity and product differentiation•Deep expertise in tissue reconstruction•Neurosurgery leadership•Unrivalled customer engagementLong-term growth and profitability•Organic growth in line with the market •Sustainable margin improvement •Impactful organic innovation in highgrowth, high margin segments •Creating value for patients, customers,and shareholders31 42 Slide 11

Page 12

Slide 12 Appendix

Page 13

AppendixTrailing twelve month adjusted EBITDA and adjusted gross margin reconciliation Slide 13 TTM Q3 2025(In millions)(495.3)GAAP Net Income43.6 Depreciation106.7 Intangible asset amortization511.4 Goodwill impairment charge1.5 Other (income), net61.3 Interest expense, net(49.9)Income tax expense/(benefit)6.9 Acquisition, divestiture and integration-related charges36.7 Structural optimization charges53.8 Boston Recall/Braintree Transition41.6 EU Medical Device Regulation813.5 Total of non-GAAP adjustments:318.2 Adjusted EBITDA1,643.0 Total Revenues19.4%Adjusted EBITDA MarginTTM Q3 2025(In millions)$859.9 Reported Gross Profit22.1 Structural optimization charges1.4 Acquisition, divestiture and integration-related charges(1)52.3 Boston Recall/Braintree Transition4.4 EU Medical Device Regulation91.8 Intangible asset amortization expense$1,031.8 Adjusted Gross Profit$1,643.0 Total Revenues62.8%Adjusted Gross MarginTrailing 12-months ended Sept. 30, 2025

Page 14

Slide 14 Non-GAAP financial disclosureIn addition to our GAAP results, we provide certain financial measures and guidance which are considered “non-GAAP” under applicable SEC rules and regulations, including adjusted earnings before interest, taxes, depreciation and amortization (“EBITDA”) margin and adjusted gross margin. Adjusted EBITDA consists of GAAP net income excluding: (i) depreciation and amortization; (ii) other income (expense); (iii) interest income and expense; (iv) income tax expense (benefit); (v) impairment charges; and (vi) those operating expenses also excluded from adjusted net income. The measure of adjusted EBITDA margin is calculated by dividing adjusted EBITDA by GAAP total revenues. The measure of adjusted gross margin is calculated by dividing adjusted gross profit by total revenues. Adjusted gross profit consists of GAAP gross profit adjusted for: (i) structural optimization charges; (ii) divestiture, acquisition and integration-related charges; (iii) charges related to the recall and the transition of Boston-related manufacturing operations to the Company's Braintree, Massachusetts facility; (iv) EU Medical Device Regulation-related charges; and (v) intangible asset amortization expense. These adjusted financial measures should not be considered in isolation or as a substitute for reported total revenues and GAAP gross margin, the most directly comparable GAAP financial measures. The Company believes that the presentation of these non-GAAP financial measures and guidance provides important supplemental information to management and investors regarding financial and business trends relating to the Company's financial condition and results of operations. Please refer to the Appendix attached to this presentation for the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures.

Slides